- Clinical Trials
- April 2024
- 100 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- February 2021
- 50 Pages
Global
From €3122EUR$3,250USD£2,687GBP
- Report
- January 2019
- 18 Pages
Global
From €9605EUR$10,000USD£8,269GBP
- Drug Pipelines
- January 2019
- 510 Pages
Global
From €21130EUR$22,000USD£18,192GBP
- Drug Pipelines
- October 2018
- 475 Pages
Global
From €21130EUR$22,000USD£18,192GBP
- Report
- June 2019
- 147 Pages
Global
From €10560EUR$10,995USD£9,092GBP
Umbralisib is a drug used to treat certain types of lymphoma, a type of cancer that affects the lymphatic system. It is a kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. It is approved for use in combination with other drugs to treat certain types of non-Hodgkin lymphoma, including marginal zone lymphoma and follicular lymphoma. It is also being studied for use in other types of cancer, such as chronic lymphocytic leukemia and multiple myeloma.
Umbralisib is a relatively new drug, and is still in the early stages of development. It is being studied in clinical trials to evaluate its safety and effectiveness in treating various types of cancer. It is also being studied in combination with other drugs to see if it can improve outcomes for patients.
The umbralisib market is a rapidly growing one, with many companies developing and marketing the drug. Some of the companies in the market include Gilead Sciences, AbbVie, and Novartis. Show Less Read more